和黃醫藥(00013.HK)合作夥伴武田取得FRUZAQLA美國食品藥監局批准
和黃醫藥(00013.HK)公布,其合作夥伴武田取得FRUZAQLA ((口夫)(口奎)替尼/fruquintinib)的美國食品藥監局(FDA)批准。這是一種口服靶向療法,用於治療既往曾接受過氟尿嘧啶類、奧沙利鉑和伊立替康為基礎的化療、抗血管內皮生長因子(VEGF)治療,以及抗表皮生長因子受體(EGFR)治療(若屬RAS野生型及醫學上適用)的成人轉移性結直腸癌患者。
FRUZAQLA是美國首個且唯一獲批用於治療經治轉移性結直腸癌的針對全部三種VEGF受體激(酉每)的高選擇性抑制劑,無論患者的生物標誌物狀態如何。
公司指出,FRUZAQLA在美國獲批觸發來自武田金額為3,500萬美元的第一筆里程碑付款,以及基於淨銷售額特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.